Breaking News: GT Biopharma Submits IND for GTB-3650 to Revolutionize CD33 Leukemia Treatment
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced the submission of an Investigational New…